Which antifungal agents are safe to use in patients with myasthenia gravis?

Antifungal Safety in Myasthenia Gravis

Fluconazole and echinocandins (caspofungin, micafungin, anidulafungin) are the safest antifungal options for patients with myasthenia gravis, while voriconazole should be avoided due to documented exacerbation of myasthenic symptoms.

Preferred Antifungal Agents

First-Line Safe Options

Fluconazole is the preferred azole antifungal for MG patients:

• Widely used across multiple candidal infections without documented neuromuscular complications 11
• Effective for candidemia, esophageal candidiasis, and urinary tract infections at standard dosing (200-800 mg daily depending on indication)
• Successfully used in an MG patient with Candida esophagitis without exacerbating symptoms 2

Echinocandins represent the safest class overall:

• Caspofungin (70 mg loading, then 50 mg daily)
• Micafungin (100-150 mg daily)
• Anidulafungin (200 mg loading, then 100 mg daily)
• No documented neuromuscular junction effects 11
• Recommended as first-line for candidemia in critically ill patients

Alternative Safe Agents

Amphotericin B formulations (conventional or lipid formulations at 3-5 mg/kg daily) have no reported MG exacerbations and are guideline-recommended for serious fungal infections 113.

Itraconazole and ketoconazole appear safe based on successful use in an MG patient with hyalohyphomycosis without reported exacerbation 4.

Antifungals to AVOID

Voriconazole - Contraindicated

Voriconazole directly exacerbates myasthenia gravis and should be avoided 5:

• Case report documented severe new-onset ophthalmoplegia and ptosis in a stable MG patient after voriconazole initiation
• Patient failed to improve with IVIG and plasmapheresis but slowly recovered only after voriconazole withdrawal
• Molecular docking studies demonstrate voriconazole binds favorably to acetylcholine receptors, potentially blocking nicotinic receptors
• The pyridine/pyrimidine moieties in voriconazole structure may be responsible for neuromuscular junction interference

Posaconazole - Use with Extreme Caution

While not directly contraindicated, posaconazole shares structural similarities with voriconazole and should be reserved for situations where no alternatives exist, with close monitoring for symptom exacerbation.

Clinical Decision Algorithm

For Candidal Infections:

1. Candidemia/invasive candidiasis: Start echinocandin (first choice) or fluconazole if not critically ill and no prior azole exposure 11
2. Esophageal candidiasis: Fluconazole 200-400 mg daily for 14-21 days 1
3. Oropharyngeal candidiasis: Fluconazole 100-200 mg daily for mild-moderate disease 11
4. Urinary candidiasis: Fluconazole 200 mg daily for 2 weeks 11

For Cryptococcosis (documented in MG patients 3):

• Induction: Amphotericin B + flucytosine
• Consolidation/maintenance: Fluconazole 400-800 mg daily
• Avoid voriconazole even for fluconazole-resistant isolates

For Aspergillosis:

• Use amphotericin B formulations instead of voriconazole
• If mold coverage absolutely required and amphotericin contraindicated, consider posaconazole with intensive monitoring, but this is suboptimal

Critical Caveats

Infection itself can trigger MG exacerbations 67:

• Underlying infection was the most common confounder in antibiotic-associated MG exacerbations (88.2%)
• Pneumonia is the leading infectious cause of mortality in MG patients
• Do not delay appropriate antifungal therapy due to MG concerns—untreated fungal infections carry higher mortality risk than potential drug effects

Drug interactions with immunosuppressants 3:

• Azole antifungals (especially fluconazole) inhibit CYP3A4 and can increase levels of tacrolimus, cyclosporine, and corticosteroids
• Requires therapeutic drug monitoring and dose adjustments of immunosuppressants
• Echinocandins have minimal drug interactions, making them preferable in patients on complex immunosuppressive regimens

Monitor for MG exacerbation when initiating any new antifungal:

• Increased ptosis, diplopia, dysphagia, or respiratory weakness
• Female sex, recent MG hospitalization, and diabetes increase risk of drug-associated exacerbations 6
• Have rescue therapies (IVIG, plasmapheresis) readily available for severe cases